Cargando…
Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer
BACKGROUND: Chemoresistance is a main obstacle in gastric cancer (GC) treatment, but its molecular mechanism still needs to be elucidated. Here, we aim to reveal the underlying mechanisms of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) resistance in GC. METHODS: We performed RNA sequencing...
Autores principales: | Zhu, Mengxuan, Zhang, Pengfei, Yu, Shan, Tang, Cheng, Wang, Yan, Shen, Zhenbin, Chen, Weidong, Liu, Tianshu, Cui, Yuehong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740411/ https://www.ncbi.nlm.nih.gov/pubmed/34996504 http://dx.doi.org/10.1186/s13046-021-02224-x |
Ejemplares similares
-
Phase I study of adjuvant chemotherapy with nab‐paclitaxel and S‐1 for stage III Lauren's diffuse‐type gastric cancer after D2 resection (NORDICA study)
por: Cui, Yuehong, et al.
Publicado: (2022) -
nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017) -
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
por: Kokubu, Hiraku, et al.
Publicado: (2023) -
Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023) -
Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)